—
This content is for informational purposes only and is not intended to provide medical advice.
A blood draw may take less than a minute, but a woman can still leave her doctor’s office without the information she came for. The sample may need to travel to a laboratory, where it is processed before the results return to the practice. Plasmatrix Biotech founder and CEO Zulma Guillot is developing technology intended to shorten that process.
“Women’s health has historically faced gaps in research, investment and diagnostic innovation,” Guillot said in a recent interview. “When clinicians do not have the information they need at the time they need it, patients feel that gap. It affects the care experience and the decisions that come next.”
Point-of-care diagnostics attempt to bring testing and treatment closer together. In plain language, the term refers to tests performed at or near the place where a patient receives care. Blood glucose checks and some rapid tests conducted in clinics are familiar examples.
With hormone testing, the blood may be drawn at the doctor’s office while the analysis takes place somewhere else. That separates the test from the conversation the patient is having with her clinician. When the result arrives later, the practice may need to call the patient, send a message or schedule another appointment to discuss it.
Central laboratories remain essential for processing large numbers of samples and conducting complex tests. Point-of-care technology is not meant to replace them. It offers a potential alternative for appropriate tests that can be performed inside a clinic while meeting the standards required for medical use.
That timing can matter in fertility care, reproductive endocrinology and menopause management. Clinicians may need to consider hormone levels alongside symptoms, medical history, previous results and treatment plans. A hormone result is not a diagnosis by itself, but having that information sooner could help the clinician and patient continue a conversation that might otherwise be interrupted by days of waiting.
Getting a result faster, however, is only useful if the technology fits naturally into patient care.
“A medical technology isn’t useful simply because it works technically,” Guillot said. “It also has to fit into the way clinicians and patients actually receive care. That means keeping both the patient and provider workflow at the center of development.”
The question also involves access, she added. Practices near major medical centers may have extensive laboratory services nearby, while smaller or more remote clinics may rely more heavily on transporting samples. Point-of-care diagnostics could eventually provide another option in some settings, but only if the technology proves accurate, practical and reliable.
What Is Plasmatrix Biotech?
Plasmatrix Biotech is a Miami-based company developing a fully automated benchtop analyzer for women’s health diagnostics. A benchtop analyzer is a compact machine designed to sit on a counter inside a medical practice rather than operate within a central laboratory.
The analyzer is being developed to work with a single-use cartridge containing a small blood sample. The cartridge is described as multiplex, meaning it is intended to measure more than one marker. Plasmatrix is designing the system to provide reproductive hormone information in about 20 minutes.
Its initial development work includes bioavailable estradiol and core reproductive endocrinology testing. Estradiol is a form of estrogen. The company is exploring potential uses in fertility diagnostics, in vitro fertilization care, obstetrics and gynecology practices, post-partum depression and menopause management.
The platform remains under development and is not commercially available. Plasmatrix must complete analytical and clinical validation, manufacturing preparation and the necessary regulatory process before the system could be used in routine patient care.
Zulma Guillot founded the company in 2020 after more than 15 years in health care operations. That experience taught her to evaluate medical technology from the perspective of the people who would have to use it, not only the scientists and engineers building it.
“Point-of-care diagnostics require assay chemistry, microfluidics, optics, mechanical engineering, software, manufacturing, quality systems and regulatory strategy to operate as one integrated product,” Guillot said.
In other words, the device is more than a machine that reads blood. Its chemistry must identify the intended markers, its cartridge must handle the sample correctly and its software must produce a result that a clinician can understand. Each part must work with the others.
The clinical setting creates another set of demands. How much training will employees need? Who will load the cartridge? Where will the machine sit? How will results appear in the patient’s record? A device can perform well during development and still be impractical during a busy day at a fertility or obstetrics and gynecology practice.
Plasmatrix is designing its analyzer for professional settings, not home use. A clinician would interpret the result alongside the patient’s symptoms, history and other medical information. That distinction is important because precision medicine is not simply about collecting more data. The information must reach someone qualified to put it into context.
Zulma Guillot: ‘We Have To Move With Purpose While Building the Evidence’
Plasmatrix’s goal of producing reproductive hormone information in about 20 minutes is the part a patient can easily picture. Reaching that goal requires a much longer process behind the scenes.
The company must first demonstrate that its analyzer can measure the intended markers accurately and consistently. Clinical validation would then evaluate how the system performs with the patients and in the settings where it is designed to be used. Manufacturing plans must ensure that cartridges can be produced to the same standards in larger quantities.
Guillot views each requirement as part of building a product clinicians can trust.
“We cannot skip scientific or regulatory steps because the need is urgent,” Guillot said. “We have to move with purpose while building the evidence, quality systems and manufacturing readiness required for a medical technology. Accessibility cannot come at the expense of rigor.”
Plasmatrix is now focused on final development, analytical and clinical validation, design for manufacture and regulatory readiness. The company is also pursuing strategic capital and manufacturing partnerships to support its next stage of growth.
Those priorities reflect the complexity of turning a promising diagnostic concept into a dependable clinical product, Guillot shared. The chemistry, cartridge, analyzer, software and quality controls must operate as one system. The final product would also need to fit into a medical practice without placing unnecessary demands on clinicians or staff.
If successfully validated, the benchtop format could eventually give some practices a way to obtain certain reproductive hormone information without sending every sample through an off-site laboratory workflow. That could be particularly valuable in communities where access to extensive laboratory infrastructure is limited.
Guillot’s work is also drawing broader recognition. Acquisition International recently named her the 2026 Most Influential Medical Operations & Innovation Advocate for Florida, recognizing her work at the crossroads of health care operations and diagnostic innovation.
Plasmatrix is still completing the work required to reach that point, but its direction is clear. Guillot is building the company around a practical question with broad relevance to women’s health: How can clinicians receive useful diagnostic information sooner while maintaining the accuracy and scientific discipline medicine requires? Her answer is taking shape one milestone at a time, through a Miami biotech company designed around the needs of both patients and providers.
—
